OKE
56
3
NFLX
36
-7
SJM
14
-2
PAYX
45
7
ITW
40
3
PFE
50
2
PHM
52
-7
DAL
79
2
DE
48
5
TDC
84
-2
MSFT
40
-4
KR
49
-3
FSLR
57
-6
T
35
-3
WEC
43
-2
GT
55
9
CINF
58
-2
GS
72
2
GM
79
4
ECL
55
-7
OKE
56
3
NFLX
36
-7
SJM
14
-2
PAYX
45
7
ITW
40
3
PFE
50
2
PHM
52
-7
DAL
79
2
DE
48
5
TDC
84
-2
MSFT
40
-4
KR
49
-3
FSLR
57
-6
T
35
-3
WEC
43
-2
GT
55
9
CINF
58
-2
GS
72
2
GM
79
4
ECL
55
-7
Financhill
Back

ACADIA Pharmaceuticals, Inc. 10K Form

Buy
56

ACAD
ACADIA Pharmaceuticals, Inc.

Last Price:
$26.55
Seasonality Move:
15.5%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2024-05-09 10Q ACAD/ACADIA Pharmaceuticals, Inc. Quarterly
2024-02-28 10K ACAD/ACADIA Pharmaceuticals, Inc. Annual
2023-11-03 10Q ACAD/ACADIA Pharmaceuticals, Inc. Quarterly
2023-08-03 10Q ACAD/ACADIA Pharmaceuticals, Inc. Quarterly
2023-05-08 10Q ACAD/ACADIA Pharmaceuticals, Inc. Quarterly
2023-02-28 10K ACAD/ACADIA Pharmaceuticals, Inc. Annual

Receive ACAD News And Ratings

See the #1 stock for the next 7 days that we like better than ACAD

ACAD Financial Statistics

Sales & Book Value

Annual Sales: $957.8M
Cash Flow: $73.9M
Price / Cash Flow: 44.04
Annual Sales: $5.42
Price / Book: 4.77

Profitability

EPS (TTM): 1.55420
Net Income (TTM): $261.2M
Gross Margin: $861M
Return on Equity: 34.23%
Return on Assets: 22.31%

ACADIA Pharmaceuticals, Inc. Earnings Forecast

Key ACADIA Pharmaceuticals, Inc. Financial Ratios

  • The Gross Profit Margin over the past 20 years for ACAD is 89.89%.
  • The Selling, General & Administrative Expenses for ACAD have been equal to 50.99% of Gross Profit Margin.
  • The Research & Development expenses have been 31.66% of Revenue.
  • The Interest Expense is 0.00% of Operating Income.
  • The Net Earning history of ACAD is 23.64% of Total Revenues.
  • Per Share Earnings over the last 25 years have been positive in 12 years.

ACADIA Pharmaceuticals, Inc. Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: ACAD
CUSIP: 004225
Website: acadia.com

Debt

Debt-to-Equity Ratio: 0.06
Current Ratio: 3.02
Quick Ratio: 2.7

Price-to-Earnings

Trailing P/E Ratio: 19.01
Forward P/E Ratio: 31.92

ACAD Technical Analysis vs Fundamental Analysis

Buy
56
ACADIA Pharmaceuticals, Inc. (ACAD) is a Buy

Is ACADIA Pharmaceuticals, Inc. a Buy or a Sell?